MannKind Corporation
28903 North Avenue Paine
Valencia
California
91355
U.S.A.
Phone:
661-775-5300
Fax:
661-775-2081
|
|
MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.
MannKind is focusing on three areas:
First, we are continuing to execute the Technosphere® Insulin clinical trial program.
Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.
Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.
Our values, like our work, combine the vision of our founder with the pragmatism of the laboratory. Teamwork, communication, trust and respect sum up the way we work and the way we treat our colleagues, while accountability, quality, and execution motivate the results we achieve. Finally, integrity and enthusiasm describe the spirit we bring to our jobs.
With around six hundred employees and three locations (in California, New Jersey, and Connecticut), we have grown significantly from our founding in 1991. We continue to be a tight-knit community where each of us has a critical role in our success. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better.
Last Updated: 04-01-2008
Email:
Ownership:
Public
Web Site:
MannKind Corporation
Employees:
Symbol: MNKD
|